| Title | Guidelines for the treatment of bacterial vaginosis: focus on tinidazole. | | Author(s) | Dickey LJ, Nailor MD, Sobel JD | | Institution | Department of Pharmacy Services, Detroit Receiving Hospital, Detroit, MI, USA. | | Source | Ther Clin Risk Manag 2009 Jun; 5(3):485-9. | | Abstract | Bacterial vaginosis (BV) is a complex vaginal infection most commonly associated with women of child-bearing age. Risk factors for BV are numerous. There are currently multiple clinical and laboratory tests for diagnosis of BV, including the most commonly used diagnostic methods: Amsel's criteria or Nugent's Gram stain scale. The mainstay of BV therapy is metronidazole, but tinidazole as well as a few other agents have also been used successfully. Tinidazole is the second nitroimidazole antiprotozoal agent and a structural derivative of metronidazole. With a favorable pharmacokinetic profile and reduced side effects, tinidazole is an alternative agent for BV treatment. There are minimal head-to-head comparative data to establish tinidazole's superiority to metronidazole or other therapeutic agents. Available data suggest tinidazole has a role in special populations particularly for refractory or relapsing BV. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19707258 |
|
